EUCTR2011-000814-21-ES进行中（未招募）不适用
A phase II, multicentre, randomized, double-blind study withsubcutaneous immunotherapy at different doses, in parallel groups andplacebo controlled in patients with rhinoconjunctivitis ± asthmasensitized to Phleum pratense.
BIAL INDUSTRIAL FARMACEUTICA, S.A.0 个研究点目标入组 150 人开始时间: 2012年1月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Dose finding clinical study, multicentre, with allergy vaccines for patients allergic to Phleum pratense pollen at different doses and placebo, a substance with inactive ingredients of medicine and whose appearance is identical to that of the actual treatment in question.EUCTR2011-000814-21-PTBIAL INDUSTRIAL FARMACEUTICA, S.A.150
进行中（未招募）
1 期
A study to test how well a new medicine called sirukumab works in patients with Severe Uncontrolled Asthmasubjects with severe, poorly controlled asthmaMedDRA version: 19.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2016-001244-19-ESGlaxoSmithKline, S.A.175
已完成
不适用
A phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to compare the efficacy, safety and tolerability of PSD502, delivered topically onto the upper vagina and cervix, to placebo in controlling discomfort/pain intensity in subjects undergoing outpatient hysteroscopyISRCTN46090514Plethora Solutions Limited (UK)24
未知
2 期
A Phase II study of T-4288 in patients with community-acquired pneumoniaCommunity-acquired pneumoniaJPRN-jRCT2080222672Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
进行中（未招募）
1 期
A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage of ILT-101 with active moderate to severe systemic lupus erythematosus(SLE)EUCTR2016-000488-17-FRILTOO PHARMA100